Skip to main content
SpringerLink
Log in

Pharmacoeconomic data support the use of SSRIs in depression

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression. A critical review. CNS Drugs 2001; 15(1): 59–83

    Article  PubMed  CAS  Google Scholar 

  2. Wilde MI, Benfield P. Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998 May; 13(5 pt 1): 543–61

    Article  PubMed  CAS  Google Scholar 

  3. Revicki DA, Wood M. Health state utilities of patients with depression. J Affect Disord 1998; 48: 25–36

    Article  PubMed  CAS  Google Scholar 

  4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the medical outcomes study. J Am Med Assoc 1989; 262: 914–19

    Article  CAS  Google Scholar 

  5. Broadhead EW, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiology survey. JAMA 1990; 264: 2524–28

    Article  PubMed  CAS  Google Scholar 

  6. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761–68

    Article  PubMed  CAS  Google Scholar 

  7. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998; 47: 446–52

    PubMed  CAS  Google Scholar 

  8. Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med 1998; 158(6): 626–32

    Article  PubMed  CAS  Google Scholar 

  9. Greenberg PE, Stiglin LE, Finkelstein SN, et al. Depression: a neglected major illness. J Clin Psychiatry 1993 Nov; 54: 419–24

    PubMed  CAS  Google Scholar 

  10. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18

    PubMed  CAS  Google Scholar 

  11. Glaser M. Annual Rx survey. Drug Top 1997; 141: 45–53

    Google Scholar 

  12. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–87

    Article  PubMed  CAS  Google Scholar 

  13. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995; 273(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  14. Sclar DE, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395–412

    PubMed  CAS  Google Scholar 

  15. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 1999; 5(5): 597–606

    PubMed  CAS  Google Scholar 

  16. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of Citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999; 19(5) Suppl. 1: 47S–54S

    Article  PubMed  CAS  Google Scholar 

  17. Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47–58

    Article  PubMed  CAS  Google Scholar 

  18. Hylan TR, Kotsanos JG, Anderson JS, et al. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am J Manag Care 1996; 2: 1211–23

    Google Scholar 

  19. Simon GE, VonKorff M, Heiligenstein JH. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275(24): 1897–1902

    Article  PubMed  CAS  Google Scholar 

  20. Simon GE, Heiligenstein JH, Revicki D, et al. Long-term outcomes of initial antidepressant drug choice in a ‘real world’ randomized clinical trial. Arch Fam Med 1999; 8: 319–25

    Article  PubMed  CAS  Google Scholar 

  21. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998; 13(1 Pt 2): 157–69

    Article  PubMed  CAS  Google Scholar 

  22. Mulrow CD, Williams JW, Trivedi M, et al. treatment of depression: newer pharmacotherapies. Evidence report/technology assessment no. 7. AHCPR publication no. 99-E014. Rockville, MD: Agency for Health Care Policy and Research, Feb 1999

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacoeconomic data support the use of SSRIs in depression. Drugs Ther. Perspect 18, 23–26 (2002). https://doi.org/10.2165/00042310-200218030-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218030-00009

Keywords

Search

Navigation